Clinical trials in Mainz – page 29

610 clinical trials in Mainz, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Mainz at a glance

610

clinical trials

Research sites1

Quick filters

610 trials in Mainz

Open in trial search

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Placebo
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Hidradenitis

Not recruiting

A study to evaluate the effectiveness and safety of zasocitinib in patients with moderate to severe hidradenitis suppurativa

Investigational

A study to evaluate the effectiveness and safety of zasocitinib in patients with moderate to severe hidradenitis suppurativa

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Exelixis Inc.

Contact Research Centre

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Germany

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Sodium Chloride
Sponsor:Moderna Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Cabozantinib
Sponsor:Ipsen Innovation

Contact Research Centre

Gastric cancer+6

Not recruiting

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo

A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cldn6 Car-T
Sponsor:BioNTech Cell & Gene Therapies GmbH

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:BioNTech SE

Contact Research Centre

Alcoholic liver disease

Not recruiting

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Investigational

A study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:AstraZeneca AB

Contact Research Centre

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:BioNTech SE

Contact Research Centre

Small cell lung cancer extensive stage+2

Not recruiting

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

InvestigationalNo placebo

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:AIO-Studien gGmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Mainz

What the registry says about research in the country

01 Infectious Disease Prevention

Groundbreaking trials focusing on viral infections including studies of vaccines against respiratory syncytial virus, Herpes Zoster, and Cytomegalovirus. Research aims to evaluate vaccine efficacy and immune response in different age groups.

RSV and hMPV Prevention
Herpes Zoster Protection
CMV Vaccine Development

Special attention is given to protecting vulnerable populations, including older adults and those at increased risk.

02 Oncology Research

Innovative clinical trials targeting various forms of cancer, including studies on breast cancer, pancreatic cancer, and multiple myeloma. Research focuses on novel therapeutic approaches and combination treatments.

Advanced Breast Cancer Therapy
Gastric Cancer Treatment
Lymphoma Management

Emphasis on personalized medicine approaches and targeted therapies for better patient outcomes.

03 Chronic Disease Management

Comprehensive studies addressing respiratory conditions, autoimmune disorders, and metabolic diseases. Research includes treatments for asthma, multiple sclerosis, and obesity.

Pulmonary Hypertension
Chronic Kidney Disease
Autoimmune Conditions

Focus on developing long-term treatment solutions and improving quality of life for patients.

Back to Germany All countries